Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03752047
Other study ID # PMD-CS-006ii
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 23, 2017
Est. completion date November 21, 2017

Study information

Verified date November 2018
Source PMD Solutions
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.

The RR trend will be measured as the difference between the RR recorded by the device at a point 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.


Description:

The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.

The RR trend will be measured as the difference between the RR recorded by the device at a point 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.

Secondary objective The secondary objective is to test if Respiratory Rate can help identify patients at increased risk of 30 day mortality.

The null Hypotheses of the planned comparison is that there is no difference in the RR trend in the 3 hours following commencement of treatment for sepsis in subjects who have an increase in SOFA score by 2 or more points and those who have a change in SOFA score of +1 or less.

The change in SOFA score will be measured at point of commencement of treatment and at 6 hours following commencement of treatment, or nearest available SOFA score determination.

Respiratory Rate captured during admission could have a predictive course for cohort of interest

The time points for reviewing the RR will be as follows:

(i) The last measurement (ii) The trend over 3 hours following commencement of treatment as per the standard of care for patients suspected of being septic.

(iii) The trend over the entire duration of admission


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date November 21, 2017
Est. primary completion date September 9, 2017
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria

- = 18 Years

- Admitted for a minimum of 12 hours

- Have been diagnosed with sepsis

Sepsis diagnosis confirmed by documented or suspected infection (ordering of blood culture or other microbiological investigation by the clinician) and =1 of the following presenting within the first 4 hours of admission:

- Fever or hypothermia, Core temperature > 38.3 or < 36 °C

- Heart rate > 90/min

- Respiratory rate > 20/min

- Altered consciousness/mental state, defined as GCS < 15

- Hyperglycemia, (BS > 6.7 mmol/L non-diabetic)

- LKC > 12 *10^9 or < 4*10^9,

- Normal LKC with > 10 % immature cells,

- CRP > highest normal local lab. Interval

- Hypotension: Systolic BP <90 mmHg, or drop in systolic BP > 40

- Hypoxemia: PaO2 < 8.5 Kpa or PaO2/FiO2 < 40 or tissue perfusion: P-lactate > 1.6

- Creatinine . 177 µmol/L

- Acute oliguria (Diuresis per hour ,0.5 ml/kg/t or 45 ml/t in 2 hours)

- Coagulopathy: Spontaneous INR > 1.5, or apt > 60 sec, thrombocytopenia

- Paralytic ileus (absence of bowel sounds)

- Hyperbilirubinemia > 34µmol/L

- Are willing to voluntarily sign a statement of informed consent to participate in this investigation

Exclusion criteria

- Allergic to medical grade skin adhesive

- Pregnant women during second and third trimester

- Continuous long term steroid use. Defined as not using steroids in the 4 weeks previous to enrolment

- Patients under the influence of substance abuse (drug or alcohol) that may interfere with their ability to cooperate and comply with the investigation procedures

- Any disorder, including cognitive dysfunction, which would affect the ability to accurately complete questionnaires and freely give full informed consent. This will be determined by the Abbreviated Mental Test Score (AMT) Cannot be followed a second time if admitted again at a later date during the study period

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Hospital of South West Jutland, Department of Emergency Medicine Esbjerg South West Jutland

Sponsors (2)

Lead Sponsor Collaborator
PMD Solutions Hospital of South West Jutland

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Upward trend in Respiratory Rate as a predictor of 30 day readmission. The secondary endpoint is the 30 day readmission rate after discharge. 30 days after discharge
Primary RespiraSense triggered escalation in SOFA score Escalation of SOFA score by 2 or more points. The primary endpoint will be evaluated with an ANCOVA with escalation of SOFA score by 2 or more points as a factor and mean RR in the first hour of treatment as a covariate. 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.
Secondary Upward trend in Respiratory Rate as a predictor of 30 day mortality The secondary endpoint is the 30 day mortality rate after discharge. 30 days after discharge
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3